ABL Bio Inc.
Research ABL Bio Inc. (298380.KQ) on Bullrun: market cap KRW 2.43T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker298380.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 2.43T
- Financial periodQ2 2026
- RevenueKRW 19.70B
- Net income-KRW 14.72B
- Free cash flow-KRW 23.97B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 2.43T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 2.43T | n/a | n/a | n/a |
Dividend history
About ABL Bio Inc.
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ABL Bio Inc.'s market cap?
ABL Bio Inc.'s market capitalization is KRW 2.43T.
What does ABL Bio Inc. do?
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc.